ADME Toxicology Testing Market to grow with a CAGR of 9.30% through 2029
Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global ADME Toxicology Testing Market in the forecast period 2025-2029
According
to TechSci Research report, “Global ADME Toxicology Testing Market Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2019-2029”, Global ADME Toxicology Testing
Market has valued at USD 8.30 billion in 2023 and is anticipated to witness an
impressive growth in the forecast period with a CAGR of 9.30% through 2029. This
can be due to collaborations and partnerships among leading companies with a
diverse approach to merge the expertise of individual companies and to
strengthen their position in the market. The demand for personalized medicine
is a significant driver of the Global ADME (Absorption, Distribution,
Metabolism, and Excretion) Toxicology Testing Market. Personalized medicine,
also known as precision medicine, is an innovative approach to healthcare that
tailor’s medical treatment and drug therapies to individual patients based on
their genetic, environmental, and lifestyle factors. Personalized medicine
often relies on genetic information to customize treatment plans. Genetic
variations can significantly impact how individuals metabolize drugs and
respond to treatment. ADME testing is essential to assess how drugs will be
absorbed, distributed, metabolized, and excreted in patients with specific
genetic profiles. Pharmacogenomics is a key component of personalized medicine
that focuses on how an individual's genetic makeup influences their response to
medications. ADME toxicology testing plays a crucial role in understanding the
relationship between genetic variations and drug metabolism. ADME testing helps
determine the optimal dosing regimens for individual patients. Understanding
how a drug behaves in the body allows healthcare providers to prescribe the
right drug at the right dose, improving therapeutic outcomes and minimizing
adverse effects. Personalized medicine aims to enhance patient safety by
minimizing the risk of adverse drug reactions. ADME testing helps identify
potential safety concerns and tailor treatment plans to reduce these risks.
Browse
over XX market data Figures and spread through XX Pages and an in-depth TOC on
" Global ADME Toxicology Testing Market”
In March 2023, Agilent Technologies Inc. has announced
its acquisition of e-MSion, an emerging company responsible for developing the innovative
ExD cell, a breakthrough electron capture dissociation (ECD) technology. The
ExD cell, a compact attachment for mass spectrometers, empowers biological
researchers to expedite the development of biotherapeutic solutions for various
diseases. It accomplishes this by facilitating a more comprehensive and precise
breakdown of the chemical bonds within complex biomolecules. This enhanced
process yields more exhaustive, precise, and intricate structural data from
these biomolecules. What's noteworthy is that the ExD cell is compatible with
commonly used laboratory instruments, including Agilent's 6500 LC/Q-TOF series.
This means that the powerful characterization technology, previously limited to
a select few high-end mass spectrometers, will now become more accessible to a
broader spectrum of laboratories and biopharmaceutical researchers around the
world.
Inter-individual
variability, which refers to differences in the way individuals respond to
drugs and toxic substances, is a significant challenge in the Global ADME
(Absorption, Distribution, Metabolism, and Excretion) Toxicology Testing
Market. Inter-individual variability impacts dosing regimens. It's essential to
determine the right dose for each patient, as factors like genetics, age,
gender, and underlying health conditions can influence drug metabolism. ADME
testing must account for variability in drug metabolism and toxicity responses.
This involves assessing how different individuals may experience varying
degrees of efficacy and safety when taking the same drug. Genetic variations,
such as single nucleotide polymorphisms (SNPs), play a crucial role in
inter-individual variability. These genetic differences can affect drug
metabolism enzymes, transporters, and receptors, leading to differing drug
responses. Variability in drug responses can result in complex drug-drug
interactions. Assessing these interactions is challenging, especially in the
presence of diverse patient profiles. Clinical trial design must account for
inter-individual variability. Larger and more diverse patient populations are
often required to detect these variations and ensure that drug efficacy and
safety are adequately evaluated. Population pharmacokinetics is a method used
to model drug behavior across diverse patient populations. This approach is
used to address inter-individual variability in drug pharmacokinetics and
optimize dosing.
Global ADME Toxicology Testing Market is segmented based
on Technology, Application, Method, and by region.
Based on the Application, Global ADME Toxicology
Testing Market is segmented into Neurotoxicity,
Renal Toxicity, Systemic Toxicity, Hepatotoxicity, and others. Hepatotoxicity, in the context of ADME
(Absorption, Distribution, Metabolism, and Excretion) Toxicology Testing,
refers to the assessment of potential liver toxicity caused by drug compounds
or other substances. The liver plays a central role in the metabolism of drugs
and xenobiotics (foreign substances), and it is susceptible to damage by
certain compounds. Evaluating hepatotoxicity is crucial to ensure the safety of
drugs and to understand how they may affect the liver. Hepatotoxicity is a leading cause of drug
withdrawals and post-market safety concerns. Therefore, it's crucial to
identify and mitigate the risks associated with liver toxicity during the drug
development process.
Based on Region, North America held the largest share in the Global ADME Toxicology Testing Market.
North American companies and research institutions have been at the forefront
of developing and implementing advanced ADME testing technologies and
methodologies. This technological leadership attracts clients from around the
world seeking state-of-the-art testing services. The region fosters
collaboration and networking among academia, industry, and government agencies.
This environment of cooperation accelerates research, innovation, and the
adoption of new ADME testing solutions. North America has a well-educated and
skilled workforce, including scientists, researchers, and laboratory
technicians, which is essential for conducting complex ADME testing. High
prevalence of diseases, a growing aging population, and the constant demand for
novel pharmaceuticals drive the need for ADME toxicology testing in North
America.
Some
of the major companies operating in the Global
ADME Toxicology Testing Market include:
- Thermo
Fisher Scientific Inc.
- Promega
Corporation
- Agilent
Technologies, Inc.
- Curia
Global, Inc.
- Dassault
Systèmes
- Beckman
Coulter, Inc., (Danaher)
- Catalent,
Inc
- Charles
River Laboratories
- GE
HealthCare
- Miltenyi
Biotec
Download Free Sample Report
Customers can also request 10% free
customization on this report
“Certain areas, particularly in North
America, are projected to exert significant demand for ADME Toxicology Testing.
The growth in the competitive landscape and the presence of well-established
companies in the market, committed to enhance the overall wellbeing of people each
year, are expected to contribute to a remarkable growth of the Global ADME
Toxicology Testing Market in the forecast period," said Mr. Karan Chechi,
Research Director with TechSci Research, a research-based Global management
consulting firm.
ADME Toxicology Testing Market by Technology (Cell Culture, OMICS Tech, High
Throughput, Molecular Imaging), By Application (Neurotoxicity, Renal Toxicity,
Systemic Toxicity, Hepatotoxicity,
others), By Method (Cellular Assay, In-Silica, Biochemical Assay, Ex-vivo), By
Region, By Competition Forecast
& Opportunities, 2019-2029 has evaluated the future growth potential
of Global ADME Toxicology Testing Market and provides statistics &
information on market size, structure, and future market growth. The report
intends to provide innovative market intelligence and help decision makers take
sound investment decisions. Besides, the report also identifies and analyzes
the emerging trends along with essential drivers, challenges, and opportunities
in Global ADME Toxicology Testing Market.
Contact
Techsci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel:
+13322586602
Email: [email protected]
Website: www.techsciresearch.com